Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Nov;40(11):1293-9.
doi: 10.1097/00004583-200111000-00009.

Multisite, double-blind, placebo-controlled trial of porcine secretin in autism

T Owley  1 , W McMahon, E H Cook, T Laulhere, M South, L Z Mays, E S Shernoff, J Lainhart, C B Modahl, C Corsello, S Ozonoff, S Risi, C Lord, B L Leventhal, P A Filipek
Affiliations
Clinical Trial

Multisite, double-blind, placebo-controlled trial of porcine secretin in autism

T Owley et al. J Am Acad Child Adolesc Psychiatry. 2001 Nov.

Abstract

Objective: To examine the efficacy of intravenous porcine secretin for the treatment of autistic disorder.

Method: Randomized, double-blind, placebo-controlled, crossover design. Fifty-six subjects with autistic disorder received either a secretin or placebo infusion at baseline and the other substance at week 4. Subjects were given the Autism Diagnostic Observation Schedule (ADOS) and other pertinent developmental measures at baseline and at weeks 4 and 8 to assess drug effects.

Results: For the primary efficacy analysis, change of ADOS social-communication total score from week 0 to week 4, no statistically significant difference was obtained between placebo (-0.8 +/- 2.9) and secretin groups (-0.6 +/- 1.4; t54 = 0.346, p < .73). The other measures showed no treatment effect for secretin compared with placebo.

Conclusion: There was no evidence for efficacy of secretin in this randomized, placebo-controlled, double-blind trial.

PubMed Disclaimer

Publication types

LinkOut - more resources